Advertisement
The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.
Advanced searchSave search
Case Anecdotes, Comments and Opinions| Volume 37, ISSUE 7, P933-936, July 2018

Download started.

Ok

First-in-man use of the MVAD axial-flow pump: Long-term outcome

Published:April 24, 2018DOI:https://doi.org/10.1016/j.healun.2018.04.012
First-in-man use of the MVAD axial-flow pump: Long-term outcome
Previous ArticleLate manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis
Next ArticleThe “right” patients for temporary mechanical circulatory support
      The use of durable continuous-flow mechanical assist devices provides selected heart failure patients with both symptomatic and functional benefits; however, they are not without potential complications. Infection, thrombosis, stroke, and gastrointesinal bleeding are among the most commonly reported problems of left ventricular assist device (LVAD) therapy.
      • Kirklin J.K.
      • Naftel D.C.
      • Pagani F.D.
      • et al.
      Seventh INTERMACS annual report: 15,000 patients and counting.
      J Heart Lung Transplant. 2015; 34: 1495-1504
      , 
      • Stulak J.M.
      • Davis M.E.
      • Haglund N.
      • et al.
      Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences.
      J Thorac Cardiovasc Surg. 2016; 151: 177-189
      , 
      • Estep J.D.
      • Starling R.C.
      • Horstmanshof D.A.
      • et al.
      Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study.
      J Am Coll Cardiol. 2015; 66: 1747-1761
      In addition, LVAD peripherals can be bulky and heavy for the patient to carry, causing joint stress, discomfort, and reduced quality of life. Device miniaturization is one design trend that has enabled device implantation in patients with a broader range of body sizes, and, when used with minimally invasive approaches, has reduced surgical trauma and complications such as bleeding and infection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Kirklin J.K.
        • Naftel D.C.
        • Pagani F.D.
        • et al.
        Seventh INTERMACS annual report: 15,000 patients and counting.
        J Heart Lung Transplant. 2015; 34: 1495-1504
        View in Article
        • Stulak J.M.
        • Davis M.E.
        • Haglund N.
        • et al.
        Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences.
        J Thorac Cardiovasc Surg. 2016; 151: 177-189
        View in Article
        • Estep J.D.
        • Starling R.C.
        • Horstmanshof D.A.
        • et al.
        Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study.
        J Am Coll Cardiol. 2015; 66: 1747-1761
        View in Article
        • McGee Jr, E.
        • Chorpenning K.
        • Brown M.C.
        • et al.
        In vivo evaluation of the HeartWare MVAD pump.
        J Heart Lung Transplant. 2014; 33: 366-371
        View in Article
        • Cheung A.
        • Chorpenning K.
        • Tamez D.
        • et al.
        Design concepts and preclinical results of a miniaturized HeartWare platform: the MVAD system.
        Innovations. 2015; 11: 151-156
        View in Article

      Article info

      Publication history

      Published online: April 24, 2018

      Identification

      DOI: https://doi.org/10.1016/j.healun.2018.04.012

      Copyright

      © 2018 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX